This meta-analysis was planned to define the role of erythropoiesis-stimulating agents (ESAs) in gynecological cancer patients, receiving myelosuppressive treatment. Pubmed, Medline and Scopus were searched to select English-language articles. Only randomized controlled trials (RCTs) were included. Endpoints were incidence of transfusions, thrombotic events (TE), deaths, and failures. Odd ratio (OR) with 95% confidence interval (CI) was calculated using fixed or random effects model. In seven RCTs ESAs studies of 892 patients under treatment, use of ESAs correlates with a significant reduction of transfusions rate (OR=0.35; 95% CI: 0.19-0.65; p=0.008). OR for overall mortality was 1.10 (95% CI 0.82-1.49; p=0.53). ESAs OR for disease failure in 5 studies was 1.71 (95% CI: 0.90-3.24; p=0.1). This meta-analysis, even if limited by few RCTs, suggests that ESAs reduce transfusions without increasing mortality or disease progression in gynecological cancer patients receiving treatment.

Erythropoiesis-stimulating agents in gynecological malignancies: a study-level meta-analysis / Marchetti, Claudia; DE FELICE, Francesca; Palaia, Innocenza; Musio, D; Muzii, Ludovico; Tombolini, Vincenzo; BENEDETTI PANICI, Pierluigi. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 99:(2016), pp. 123-128. [10.1016/j.critrevonc.2015.12.013]

Erythropoiesis-stimulating agents in gynecological malignancies: a study-level meta-analysis

MARCHETTI, CLAUDIA
Co-primo
;
DE FELICE, FRANCESCA
Co-primo
;
PALAIA, INNOCENZA;MUZII, LUDOVICO;TOMBOLINI, Vincenzo
Penultimo
;
BENEDETTI PANICI, PIERLUIGI
Ultimo
2016

Abstract

This meta-analysis was planned to define the role of erythropoiesis-stimulating agents (ESAs) in gynecological cancer patients, receiving myelosuppressive treatment. Pubmed, Medline and Scopus were searched to select English-language articles. Only randomized controlled trials (RCTs) were included. Endpoints were incidence of transfusions, thrombotic events (TE), deaths, and failures. Odd ratio (OR) with 95% confidence interval (CI) was calculated using fixed or random effects model. In seven RCTs ESAs studies of 892 patients under treatment, use of ESAs correlates with a significant reduction of transfusions rate (OR=0.35; 95% CI: 0.19-0.65; p=0.008). OR for overall mortality was 1.10 (95% CI 0.82-1.49; p=0.53). ESAs OR for disease failure in 5 studies was 1.71 (95% CI: 0.90-3.24; p=0.1). This meta-analysis, even if limited by few RCTs, suggests that ESAs reduce transfusions without increasing mortality or disease progression in gynecological cancer patients receiving treatment.
2016
anemia; chemotherapy; erythropoiesis-stimulating agents; gynecological cancer; mortality; transfusion
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Erythropoiesis-stimulating agents in gynecological malignancies: a study-level meta-analysis / Marchetti, Claudia; DE FELICE, Francesca; Palaia, Innocenza; Musio, D; Muzii, Ludovico; Tombolini, Vincenzo; BENEDETTI PANICI, Pierluigi. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 99:(2016), pp. 123-128. [10.1016/j.critrevonc.2015.12.013]
File allegati a questo prodotto
File Dimensione Formato  
Marchetti_Erythropoiesis_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.55 MB
Formato Adobe PDF
1.55 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/875056
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact